EP Patent

EP0520032B1 — Use of spiperone as an immunosuppressant and anti-inflammatory agent

Assigned to Beth Israel Deaconess Medical Center Inc · Expires 1998-09-16 · 28y expired

What this patent protects

A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexe…

USPTO Abstract

A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.

Drugs covered by this patent

Patent Metadata

Patent number
EP0520032B1
Jurisdiction
EP
Classification
—
Expires
1998-09-16
Drug substance claim
No
Drug product claim
No
Assignee
Beth Israel Deaconess Medical Center Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.